GEFTIGET 250MG

Geftiget 250mg Tablet is an antineoplastic medication classified as a tyrosine kinase inhibitor, with Gefitinib as its active component. It is indicated for the treatment of non-small cell lung cancer (NSCLC). NSCLC is characterized by the uncontrolled and abnormal proliferation of cells within lung tissues. This medication is prescribed for patients whose NSCLC has metastasized to other areas of the body, particularly those with specific mutations in the epidermal growth factor receptor (EGFR) genes, and for individuals who have not previously undergone cancer treatment.

Certain formulations of this medication may include lactose as an inactive ingredient, which can be problematic for individuals who are lactose intolerant, as they cannot properly digest this sugar found in milk and dairy products. Symptoms of lactose intolerance may include bloating and abdominal discomfort. If you are lactose intolerant, it is important to inform your physician prior to initiating this treatment. Additionally, consult your healthcare provider if you have any history of kidney or liver disease, vision issues, lung conditions, or if you are taking anticoagulants such as warfarin. Regular blood tests will be conducted by your healthcare provider to monitor for potential complications. It is advisable to refrain from alcohol consumption, as it may lead to dizziness.

Before using this medication, consult your physician if you are pregnant or planning to conceive. These tablets are contraindicated during pregnancy due to the potential harm they may cause to an unborn child. Your healthcare provider will perform a pregnancy test prior to commencing treatment with this tablet. Discuss effective contraceptive methods with your doctor and ensure their use for at least two weeks after the final dose. It is also recommended to avoid breastfeeding while undergoing treatment, as it is unclear whether this medication is excreted in breast milk.